Vaccine manufacturer the Serum Institute of India (SII) has announced plans to make a strategic investment in IntegriMedical, acquiring a stake of 20%, to progress the development of needle-free injection system (N-FIS) technology.
The investment aligns with SII's strategy to enhance patient compliance, lower needle-stick injuries and improve the efficacy of liquid medications.
N-FIS technology employs a mechanically powered high-velocity jet stream to administer drugs and biologics.
The system is designed to offer a pain-free experience to patients, particularly those with needle phobia, making the process of medication administration more pleasant and stress-free.
N-FIS has secured regulatory approvals in India, Europe and the US. It holds International Organisation for Standardisation 13485 certification and a US patent.
Clinical trials have demonstrated the technology's ability to reduce pain and address needle-phobia.
The collaboration will combine SII’s vaccine production and global supply expertise with IntegriMedical's research capabilities and drug delivery technology.
The N-FIS is set to be introduced to the Indian private market, providing an innovative alternative to conventional needle-based injections.
The technology’s benefits include the elimination of needle phobia, pain reduction during drug administration, ease of use and the prevention of cross-contamination.
Serum Institute of India CEO Adar Poonawalla said: “At SII, we are constantly seeking opportunities to invest in technologies that align with our mission to make healthcare accessible and affordable for people worldwide.
“IntegriMedical's needle-free injection systems (N-FIS) represent a significant advancement in drug delivery and we envision a needle-free solution to deliver vaccines. We believe this could potentially revolutionise the way we administer vaccines, making the process more comfortable for patients and healthcare professionals.”
